Herbal antioxidants in dialysis patients: a review of potential mechanisms and medical implications

References

• Gorostidi M, Santamaría R, Alcázar R, et al. Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. Nefrologia. 2014;34(3):302–316.
   PubMed Web of Science ®Google Scholar
• Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. Pragmat Obs Res. 2016;7:21–32.
   PubMed Web of Science ®Google Scholar
• Elshahat S, Cockwell P, Maxwell AP, et al. The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review. PLOS One. 2020;15(3):e0230512.
   PubMed Web of Science ®Google Scholar
• Zhou D, Fu H, Zhang L, et al. Tubule-derived Wnts are required for fibroblast activation and kidney fibrosis. J Am Soc Nephrol. 2017;28(8):2322–2336.
   PubMed Web of Science ®Google Scholar
• Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–1982.
   PubMed Web of Science ®Google Scholar
• Navarro-García JA, Rodríguez-Sánchez E, Aceves-Ripoll J, et al. Oxidative status before and after renal replacement therapy: differences between conventional high flux hemodialysis and on-line hemodiafiltration. Nutrients. 2019;11(11):2809.
   Web of Science ®Google Scholar
• Mehrotra R, Devuyst O, Davies SJ, et al. The current state of peritoneal dialysis. J Am Soc Nephrol. 2016;27(11):3238–3252.
   PubMed Web of Science ®Google Scholar
• Birben E, Sahiner UM, Sackesen C, et al. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9–19.
   PubMedGoogle Scholar
• Cachofeiro V, Goicochea M, de Vinuesa SG, et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;74(111):S4–S9.
   Google Scholar
• Fujii H, Goto S, Fukagawa M. Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins. 2018;10(5):202.
   Web of Science ®Google Scholar
• Locatelli F, Canaud B, Eckardt KU, et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18(7):1272–1280.
   PubMed Web of Science ®Google Scholar
• Liakopoulos V, Roumeliotis S, Gorny X, et al. Oxidative stress in patients undergoing peritoneal dialysis: a current review of the literature. Oxid Med Cell Longev. 2017;2017:3494867.
   PubMed Web of Science ®Google Scholar
• Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial. 2009;22(6):636–643.
   PubMed Web of Science ®Google Scholar
• Maraj M, Kuśnierz-Cabala B, Dumnicka P, et al. Malnutrition, inflammation, atherosclerosis syndrome (MIA) and diet recommendations among end-stage renal disease patients treated with maintenance hemodialysis. Nutrients. 2018;10(1):69.
   PubMed Web of Science ®Google Scholar
• Liakopoulos V, Roumeliotis S, Zarogiannis S, et al. Oxidative stress in hemodialysis: causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 2019;32(1):58–71.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ren Z, Zhang J, et al. Role of ROS and nutritional antioxidants in human diseases. Front Physiol. 2018;9:477.
   PubMed Web of Science ®Google Scholar
• Liakopoulos V, Roumeliotis S, Gorny X, et al. Oxidative stress in hemodialysis patients: a review of the literature. Oxid Med Cell Longev. 2017;2017:3081856.
   PubMed Web of Science ®Google Scholar
• Chazot C, Jean G, Kopple JD. Can outcomes be improved in dialysis patients by optimizing trace mineral, micronutrient, and antioxidant status?: the impact of vitamins and their supplementation. Semin Dial. 2016;29(1):39–48.
   PubMed Web of Science ®Google Scholar
• Roumeliotis S, Roumeliotis A, Panagoutsos S, et al. Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy. J Diabetes Compl. 2017;31(10):1527–1532.
   PubMed Web of Science ®Google Scholar
• L Gupta K, Sahni N. Dietary antioxidents and oxidative stress in predialysis chronic kidney disease patients. J Nephropathol. 2012;1(3):134–142.
   PubMedGoogle Scholar
• Dai L, Golembiewska E, Lindholm B, et al. End-stage renal disease, inflammation and cardiovascular outcomes. Contrib Nephrol. 2017;191:32–43.
   PubMed Web of Science ®Google Scholar
• Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem. 2015;30(1):11–26.
   PubMed Web of Science ®Google Scholar
• Remacle J, Raes M, Toussaint O, et al. Low levels of reactive oxygen species as modulators of cell function. Mutat Res. 1995;316(3):103–122.
   PubMedGoogle Scholar
• Baragetti I, El Essawy B, Fiorina P. Targeting immunity in end-stage renal disease. Am J Nephrol. 2017;45(4):310–319.
   PubMed Web of Science ®Google Scholar
• Roumeliotis S, Eleftheriadis T, Liakopoulos V. Is oxidative stress an issue in peritoneal dialysis? Semin Dial. 2019;32(5):463–466.
   PubMed Web of Science ®Google Scholar
• Xu H, Watanabe M, Qureshi AR, et al. Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients. Perit Dial Int. 2015;35(2):206–215.
   PubMed Web of Science ®Google Scholar
• Varan HI, Dursun B, Dursun E, et al. Acute effects of hemodialysis on oxidative stress parameters in chronic uremic patients: comparison of two dialysis membranes. Int J Nephrol Renovasc Dis. 2010;3:39–45.
   PubMedGoogle Scholar
• Ogunro PS, Oluyombo R, Ajala MO, et al. The effect of a membrane dialyzer during hemodialysis on the antioxidant status and lipid peroxidation of patients with end-stage renal disease. Saudi J Kidney Dis Transpl. 2014;25(6):1186–1193.
   PubMedGoogle Scholar
• Andreoli MC, Dalboni MA, Watanabe R, et al. Impact of dialyzer membrane on apoptosis and function of polymorphonuclear cells and cytokine synthesis by peripheral blood mononuclear cells in hemodialysis patients. Artif Organs. 2007;31(12):887–892.
   PubMed Web of Science ®Google Scholar
• Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2431–2438.
   PubMed Web of Science ®Google Scholar
• Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Am J Kidney Dis. 2006;47(1):37–41.
   PubMed Web of Science ®Google Scholar
• Maher ER, Wickens DG, Griffin JF, et al. Increased free-radical activity during haemodialysis? Nephrol Dial Transplant. 1987;2(3):169–171.
   PubMedGoogle Scholar
• Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648–658.
   PubMed Web of Science ®Google Scholar
• Jofré R, Rodriguez-Benitez P, López-Gómez JM, et al. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol. 2006;17(12 Suppl 3):S274–S80.
   PubMedGoogle Scholar
• Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant. 2018;33(suppl_3):iii35–iii40.
   PubMedGoogle Scholar
• Morena M, Delbosc S, Dupuy AM, et al. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int. 2005;9(1):37–46.
   PubMedGoogle Scholar
• Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant. 2002;17(Suppl 11):28–31.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States renal data system 2003 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(6 Suppl 5):A5–7.
   PubMedGoogle Scholar
• Miyata T, Kurokawa K, Van Ypersele D, Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol. 2000;11(9):1744–1752.
   PubMed Web of Science ®Google Scholar
• Combet S, Miyata T, Moulin P, et al. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol. 2000;11(4):717–728.
   PubMed Web of Science ®Google Scholar
• Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis. 2014;64(2):278–289.
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Carvalho MJ, Stenvinkel P, et al. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int. 2006;26(1):53–63.
   PubMed Web of Science ®Google Scholar
• Witowski J, Topley N, Jörres A, et al. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int. 1995;47(1):282–293.
   PubMed Web of Science ®Google Scholar
• Kurutas EB. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state. Nutr J. 2016;15(1):71.
   PubMed Web of Science ®Google Scholar
• Roehrs M, Valentini J, Paniz C, et al. The relationships between exogenous and endogenous antioxidants with the lipid profile and oxidative damage in hemodialysis patients. BMC Nephrol. 2011;12(1):59.
   PubMedGoogle Scholar
• Liakopoulos V, Roumeliotis S, Bozikas A, et al. Antioxidant supplementation in renal replacement therapy patients: is there evidence? Oxid Med Cell Longev. 2019;2019:9109473.
   PubMed Web of Science ®Google Scholar
• Lightfoot TJ, Skibola CF, Smith AG, et al. Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica. 2006;91(9):1222–1227.
   PubMed Web of Science ®Google Scholar
• Xu D-P, Li Y, Meng X, et al. Natural antioxidants in foods and medicinal plants: extraction, assessment and resources. IJMS. 2017;18(1):96.
   Google Scholar
• Oroian M, Escriche I. Antioxidants: characterization, natural sources, extraction and analysis. Food Res Int. 2015;74:10–36.
   PubMed Web of Science ®Google Scholar
• Bungau S, Abdel-Daim MM, Tit DM, et al. Health benefits of polyphenols and carotenoids in age-related eye diseases. Oxid Med Cell Longev. 2019;2019:9783429.
   PubMed Web of Science ®Google Scholar
• Cai Y, Luo Q, Sun M, et al. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci. 2004;74(17):2157–2184.
   PubMed Web of Science ®Google Scholar
• Askari H, Zeinali F, Haghi-Aminjan H, et al. The protective effects of Ocimum basilicum extract against gentamicin-induced nephrotoxicity in male rats; an anti-inflammatory, anti-oxidative and anti-apoptotic action. Immunopathol Persa. 2019;5(2):e21-e–e21.
   Web of Science ®Google Scholar
• Alirezaei A, Argani H, Asgharpour M, et al. An update on allopurinol and kidney failure; new trend for an old drug. J Renal Inj Prev. 2017;6(4):297–302.
   Web of Science ®Google Scholar
• Sadidi M, Bakhtiyari M, Alirezaei A. Effects of the Portulaca oleracea extract on gentamicin-induced nephrotoxicity in male rats. Iran Red Crescent Med J. 2019;21(2):e83785.
   Web of Science ®Google Scholar
• Alirezaei AH, Barough AS, Azizi T, et al. Anti-inflammatory effects of grape seed extract in hemodialysis patients; a pilot study. J Renal Inj Prev. 2016;6(3):184–187.
   Web of Science ®Google Scholar
• Zare E, Alirezaei A, Bakhtiyari M, et al. Evaluating the effect of garlic extract on serum inflammatory markers of peritoneal dialysis patients: a randomized double-blind clinical trial study. BMC Nephrol. 2019;20(1):26.
   PubMedGoogle Scholar
• Veeresham C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res. 2012;3(4):200–201.
   PubMedGoogle Scholar
• Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004;1(4):24–29.
   PubMedGoogle Scholar
• Wagner H, Hörhammer L, Münster R. [On the chemistry of silymarin (silybin), the active principle of the fruits from Silybum marianum (L.) Gaertn. (Carduus marianus L.)]. Arzneimittelforschung. 1968;18(6):688–696.
   PubMedGoogle Scholar
• Borah A, Paul R, Choudhury S, et al. Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action. CNS Neurosci Ther. 2013;19(11):847–853.
   PubMed Web of Science ®Google Scholar
• Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035–2063.
   PubMed Web of Science ®Google Scholar
• Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants. 2015;4(1):204–247.
   Web of Science ®Google Scholar
• Rafieian-Kopaie M, Nasri H. Silymarin and diabetic nephropathy. J Renal Inj Prev. 2012;1(1):3–5.
   PubMedGoogle Scholar
• Soto C, Pérez J, García V, et al. Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine. 2010;17(14):1090–1094.
   PubMed Web of Science ®Google Scholar
• Féher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2012;13(1):210–217.
   PubMed Web of Science ®Google Scholar
• El-Shitany NA, El-Haggar S, El-Desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008;46(7):2422–2428.
   PubMed Web of Science ®Google Scholar
• Ninsontia C, Pongjit K, Chaotham C, et al. Silymarin selectively protects human renal cells from cisplatin-induced cell death. Pharm Biol. 2011;49(10):1082–1090.
   PubMed Web of Science ®Google Scholar
• Tan J, Hu J, He Y, et al. Protective role of silymarin in a mouse model of renal ischemia-reperfusion injury. Diagn Pathol. 2015;10(1):198.
   PubMedGoogle Scholar
• Koçarslan A, Koçarslan S, Aydin MS, et al. Intraperitoneal administration of silymarin protects end organs from multivisceral ischemia/reperfusion injury in a rat model. Braz J Cardiovasc Surg. 2016;31(6):434–439.
   PubMed Web of Science ®Google Scholar
• Homsi E, de Brito SM, Janino P. Silymarin exacerbates p53-mediated tubular apoptosis in glycerol-induced acute kidney injury in rats. Ren Fail. 2010;32(5):623–632.
   PubMed Web of Science ®Google Scholar
• Fallahzadeh MK, Dormanesh B, Sagheb MM, et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis. 2012;60(6):896–903.
   PubMed Web of Science ®Google Scholar
• Roozbeh J, Shahriyari B, Akmali M, et al. Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. Ren Fail. 2011;33(2):118–123.
   PubMed Web of Science ®Google Scholar
• Nazemian F, Karimi G, Moatamedi M, et al. Effect of silymarin administration on TNF-α serum concentration in peritoneal dialysis patients. Phytother Res. 2010;24(11):1654–1657.
   PubMed Web of Science ®Google Scholar
• Firuzi O, Khajehrezaei S, Ezzatzadegan S, et al. Effects of silymarin on biochemical and oxidative stress markers in end-stage renal disease patients undergoing peritoneal dialysis. Hemodial Int. 2016;20(4):558–563.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wei H, Lin M, et al. Curcumin protects against ischemic spinal cord injury: The pathway effect. Neural Regen Res. 2013;8(36):3391–3400.
   PubMed Web of Science ®Google Scholar
• Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017;57(13):2889–2895.
   PubMed Web of Science ®Google Scholar
• Rawat N, Alhamdani A, McAdam E, et al. Curcumin abrogates bile-induced NF-κB activity and DNA damage in vitro and suppresses NF-κB activity whilst promoting apoptosis in vivo, suggesting chemopreventative potential in Barrett's oesophagus. Clin Transl Oncol. 2012;14(4):302–311.
   PubMed Web of Science ®Google Scholar
• Joe B, Lokesh BR. Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta. 1994;1224(2):255–263.
   PubMed Web of Science ®Google Scholar
• SreejayanRao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol. 1994;46(12):1013–1016.
   PubMed Web of Science ®Google Scholar
• Soetikno V, Sari FR, Lakshmanan AP, et al. Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway. Mol Nutr Food Res. 2013;57(9):1649–1659.
   PubMed Web of Science ®Google Scholar
• Ali BH, Al‐Salam S, Al Suleimani Y, et al. Curcumin ameliorates kidney function and oxidative stress in experimental chronic kidney disease. Basic Clin Pharmacol Toxicol. 2018;122(1):65–73.
   PubMed Web of Science ®Google Scholar
• Kim KS, Lim H-J, Lim JS, et al. Curcumin ameliorates cadmium-induced nephrotoxicity in Sprague-Dawley rats. Food Chem Toxicol. 2018;114:34–40.
   PubMed Web of Science ®Google Scholar
• de Almeida Alvarenga L, de Oliveira Leal V, Borges NA, et al. Curcumin-A promising nutritional strategy for chronic kidney disease patients. J Funct Foods. 2018;40:715–721.
   Web of Science ®Google Scholar
• Li Y, Zhang J, Liu H, et al. Curcumin ameliorates glyoxylate-induced calcium oxalate deposition and renal injuries in mice. Phytomedicine. 2019;61:152861.
   PubMed Web of Science ®Google Scholar
• Joe B, Lokesh B. Dietary n-3 fatty acids, curcumin and capsaicin lower the release of lysosomal enzymes and eicosanoids in rat peritoneal macrophages. Mol Cell Biochem. 2000;203(1–2):153–161.
   PubMed Web of Science ®Google Scholar
• Khajehdehi P, Pakfetrat M, Javidnia K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study . Scand J Urol Nephrol. 2011;45(5):365–370.
   PubMed Web of Science ®Google Scholar
• Khajehdehi P, Zanjaninejad B, Aflaki E, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012;22(1):50–57.
   PubMed Web of Science ®Google Scholar
• Samadian F, Dalili N, Poor-Reza Gholi F, et al. Evaluation of Curcumin's effect on inflammation in hemodialysis patients. Clin Nutr Espen. 2017;22:19–23.
   PubMed Web of Science ®Google Scholar
• Shoskes D, Lapierre C, Cruz-Correa M, et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation. 2005;80(11):1556–1559.
   PubMed Web of Science ®Google Scholar
• Pakfetrat M, Akmali M, Malekmakan L, et al. Role of turmeric in oxidative modulation in end-stage renal disease patients. Hemodial Int. 2015;19(1):124–131.
   PubMed Web of Science ®Google Scholar
• Alvarenga L, Salarolli R, Cardozo LF, et al. Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: a pilot randomized, double-blind, controlled study. Clin Nutr. 2020;39(12):3594–3600.
   PubMed Web of Science ®Google Scholar
• Hou CY, Tain YL, Yu HR, et al. The effects of resveratrol in the treatment of metabolic syndrome. Int J Mol Sci. 2019;20(3):535.
   Web of Science ®Google Scholar
• Sadi G, Şahin G, Bostancı A. Modulation of renal insulin signaling pathway and antioxidant enzymes with streptozotocin-induced diabetes: effects of resveratrol. Medicina. 2018;55(1):3.
   PubMedGoogle Scholar
• Xu S, Gao Y, Zhang Q, et al. SIRT1/3 activation by resveratrol attenuates acute kidney injury in a septic rat model. Oxid Med Cell Longev. 2016;2016:7296092.
   PubMed Web of Science ®Google Scholar
• Bienholz A, Mae Pang R, Guberina H, et al. Resveratrol does not protect from ischemia-induced acute kidney injury in an in vivo rat model. Kidney Blood Press Res. 2017;42(6):1090–1103.
   PubMed Web of Science ®Google Scholar
• Silan C, Uzun O, Comunoğlu NU, et al. Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol. Biol Pharm Bull. 2007;30(1):79–83.
   PubMed Web of Science ®Google Scholar
• Darwish MA, Abo-Youssef AM, Khalaf MM, Abo-Saif AA, Saleh IG, et al. Resveratrol influences platinum pharmacokinetics: a novel mechanism in protection against cisplatin-induced nephrotoxicity. Toxicol Lett. 2018;290:73–82.
   PubMed Web of Science ®Google Scholar
• Chander V, Tirkey N, Chopra K. Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism. Toxicology. 2005;210(1):55–64.
   PubMed Web of Science ®Google Scholar
• Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, et al. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 2019;45(1):53–59.
   PubMed Web of Science ®Google Scholar
• Hong SH, Lee HJ, Sohn EJ, et al. Anti-nephrolithic potential of resveratrol via inhibition of ROS, MCP-1, hyaluronan and osteopontin in vitro and in vivo. Pharmacol Rep. 2013;65(4):970–979.
   PubMed Web of Science ®Google Scholar
• Wu M, Gu J, Mei S, et al. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation. Nephrol Dial Transplant. 2016;31(11):1826–1834.
   PubMed Web of Science ®Google Scholar
• Xu Y, Nie L, Yin YG, et al. Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol. 2012;259(3):395–401.
   PubMed Web of Science ®Google Scholar
• Hui Y, Lu M, Han Y, et al. Resveratrol improves mitochondrial function in the remnant kidney from 5/6 nephrectomized rats. Acta Histochem. 2017;119(4):392–399.
   PubMed Web of Science ®Google Scholar
• Zhong M, Cheng GF, Wang WJ, et al. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine. 1999;6(2):79–84.
   PubMed Web of Science ®Google Scholar
• Lin CT, Sun XY, Lin AX. Supplementation with high-dose trans-resveratrol improves ultrafiltration in peritoneal dialysis patients: a prospective, randomized, double-blind study. Ren Fail. 2016;38(2):214–221.
   PubMed Web of Science ®Google Scholar
• Saldanha JF, Leal VO, Rizzetto F, et al. Effects of resveratrol supplementation in Nrf2 and NF-κB expressions in nondialyzed chronic kidney disease patients: a randomized, double-blind, placebo-controlled, crossover clinical trial. J Ren Nutr. 2016;26(6):401–406.
   PubMed Web of Science ®Google Scholar
• Murillo Ortiz BO, Fuentes Preciado AR, Ramirez Emiliano J, et al. Recovery of bone and muscle mass in patients with chronic kidney disease and iron overload on hemodialysis and taking combined supplementation with curcumin and resveratrol. Clin Interv Aging. 2019;14:2055–2062.
   PubMed Web of Science ®Google Scholar
• Dong X, Fu J, Yin X, et al. Emodin: a review of its pharmacology, toxicity and pharmacokinetics. Phytother Res. 2016;30(8):1207–1218.
   PubMed Web of Science ®Google Scholar
• Subramaniam A, Shanmugam MK, Ong TH, et al. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol. 2013;170(4):807–821.
   PubMed Web of Science ®Google Scholar
• Chan T, Chang C, Koonchanok N, et al. Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun. 1993;193(3):1152–1158.
   PubMed Web of Science ®Google Scholar
• Battistutta R, Sarno S, De Moliner E, et al. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem. 2000;275(38):29618–29622.
   PubMed Web of Science ®Google Scholar
• Yang J, Zeng Z, Wu T, et al. Emodin attenuates high glucose-induced TGF-β1 and fibronectin expression in mesangial cells through inhibition of NF-κB pathway. Exp Cell Res. 2013;319(20):3182–3189.
   PubMed Web of Science ®Google Scholar
• Yang J, Li L. Effects of Rheum on renal hypertrophy and hyperfiltration of experimental diabetes in rat. Zhongguo Zhong xi yi Jie he za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese J Integr Trad West Med]. 1993;13(5):61–62.
   Google Scholar
• Jing D, Bai H, Yin S. Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K/Akt/GSK-3β and Bax/caspase-3 signaling pathways. Exp Ther Med. 2017;14(5):5163–5169.
   PubMed Web of Science ®Google Scholar
• Wang J, Huang H, Liu P, et al. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur J Pharmacol. 2006;553(1–3):297–303.
   PubMed Web of Science ®Google Scholar
• Tian N, Gao Y, Wang X, et al. Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy. Drug Des Devel Ther. 2018;12:2195–2211.
   PubMed Web of Science ®Google Scholar
• Zhu B, Lin Y, Zhu CF, et al. Emodin inhibits extracellular matrix synthesis by suppressing p38 and ERK1/2 pathways in TGF-β1-stimulated NRK-49F cells . Mol Med Rep. 2011;4(3):505–509.
   PubMed Web of Science ®Google Scholar
• Li D, Zhang Q, Lou Y, et al. Emodin attenuates renal interstitial fibrosis via regulation of TIMP1/MM9 pathway in rats. bioRxiv. 2019:736876.
   Google Scholar
• Ma L, Li H, Zhang S, et al. Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2. Int Urol Nephrol. 2018;50(2):373–382.
   PubMed Web of Science ®Google Scholar
• Yung S, Liu Z-H, Lai K-N, et al. Emodin ameliorates glucose-induced morphologic abnormalities and synthesis of transforming growth factor beta1 and fibronectin by human peritoneal mesothelial cells. Perit Dial Int. 2001;21(3_suppl):41–S7.
   Google Scholar
• Chan TM, Leung JK-H, Tsang RC-W, et al. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney International. 2003;64(2):519–533.
   PubMed Web of Science ®Google Scholar
• Wang H, Lin X, Fang X, et al. Emodin ameliorates the peritoneal dialysis-related peritoneal fibrosis via inhibiting the activation of notch pathway. Sheng li xue bao [Acta Physiol Sin]. 2016;68(6):747–756.
   PubMedGoogle Scholar
• Yang H, Song Y, Liang Y-N, et al. Quercetin treatment improves renal function and protects the kidney in a rat model of adenine-induced chronic kidney disease. Med Sci Monit. 2018;24:4760–4766.
   PubMed Web of Science ®Google Scholar
• Vicente-Vicente L, Prieto M, Morales A. Eficacia y seguridad de la quercetina como complemento alimenticio. Revista de Toxicología. 2013;30(2):171–181.
   Google Scholar
• Erboga M, Aktas C, Erboga ZF, et al. Quercetin ameliorates methotrexate-induced renal damage, apoptosis and oxidative stress in rats. Ren Fail. 2015;37(9):1492–1497.
   PubMed Web of Science ®Google Scholar
• Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, et al. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant. 2011;26(11):3484–3495.
   PubMed Web of Science ®Google Scholar
• Morales AI, Vicente-Sánchez C, Sandoval JM, et al. Protective effect of quercetin on experimental chronic cadmium nephrotoxicity in rats is based on its antioxidant properties. Food Chem Toxicol. 2006;44(12):2092–2100.
   PubMed Web of Science ®Google Scholar
• Kahraman A, Erkasap N, Serteser M, et al. Protective effect of quercetin on renal ischemia/reperfusion injury in rats. J Nephrol. 2003;16(2):219–224.
   PubMed Web of Science ®Google Scholar
• Lu Q, Ji X-J, Zhou Y-X, et al. Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy. Pharmacol Res. 2015;99:237–247.
   PubMed Web of Science ®Google Scholar
• Park HK, Jeong BC, Sung M-K, et al. Reduction of oxidative stress in cultured renal tubular cells and preventive effects on renal stone formation by the bioflavonoid quercetin. J Urol. 2008;179(4):1620–1626.
   PubMed Web of Science ®Google Scholar
• Kuhlmann M, Burkhardt G, Horsch E, et al. Inhibition of oxidant-induced lipid peroxidation in cultured renal tubular epithelial cells (LLC-PK1) by quercetin. Free Radic Res. 1998;29(5):451–460.
   PubMed Web of Science ®Google Scholar
• Cao Y, Hu J, Sui J, et al. Quercetin is able to alleviate TGF-β-induced fibrosis in renal tubular epithelial cells by suppressing miR-21. Exp Ther Med. 2018;16(3):2442–2448.
   PubMed Web of Science ®Google Scholar
• Riesenhuber A, Kasper DC, Vargha R, et al. Quercetin protects human mesothelial cells against exposure to peritoneal dialysis fluid. Pediatr Nephrol. 2007;22(8):1205–1208.
   PubMed Web of Science ®Google Scholar